INS.L Regulatory News (INS)

4 May 2011

Instem Life Science Systems plc

("Instem", the "Company" or the "Group")

Posting of Annual Report and Accounts

Notice of Annual General Meeting

Instem Life Science Systems plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, announces that it has today posted to shareholders the Annual Report and Accounts for the year ended 31 December 2010 together with the Notice of the Annual General Meeting to be held at 12.00pm on Tuesday 31 May 2011 at the offices of Brewin Dolphin Limited, National House, 36 St. Ann Street, Manchester, M2 7LE.

Copies of the Annual Report and Accounts will be available on Instem's website at: http://investors.instem.com/ 

For further information, please contact:

About Instem Life Science Systems plc

Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.